ELVN
Enliven Therapeutics Inc.
40.60$
-1.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -0.8% | +26.1% | -4.6% | -6.6% | +6.7% | -7.1% | +66.5% | -2.6% | -3.0% | -2.4% | +95.8% | |
| – | -0.9% | +26.7% | -5.7% | -6.6% | +7.1% | -7.5% | +68.4% | -2.6% | -1.6% | -2.5% | +95.9% | |
| – | +35.6% | +49.0% | -35.1% | +3.9% | +23.4% | -18.1% | +17.4% | -14.8% | -2.8% | +33.7% | +2.5% | |
| – | -3.9% | +26.6% | -2.5% | -6.6% | +7.4% | -7.6% | +69.4% | -2.6% | -3.1% | -2.2% | +97.9% | |
| – | +111.2% | -3.5% | -11.8% | -23.0% | -6.5% | -10.3% | +8.0% | -4.3% | +13.0% | -31.1% | +31.2% | |
| – | +114.4% | -3.3% | -11.7% | -23.0% | -6.5% | -12.2% | +8.9% | -3.7% | +13.1% | -30.7% | +23.3% | |
| – | +0.9% | -24.8% | -32.9% | -49.7% | – | – | +3.0% | +2.9% | +3.1% | -24.3% | +97.7% | |
| – | -64.4% | +412.6% | -60.3% | -5.9% | +31.7% | +16.4% | +50.5% | -39.2% | +51.1% | -24.0% | -77.4% | |
| – | -6.1% | +29.2% | -4.0% | -5.4% | +7.4% | -7.0% | +69.4% | -2.5% | -3.5% | -1.4% | +97.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +2.2% | +14.3% | +0.4% | +3.3% | +0.4% | +4.1% | +19.2% | -8.7% | +10.8% | +5.4% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.